Brief: Tarsus Doses First Participant In Calliope, A Phase 2 Clinical Trial Of Tp-05 (Lotilaner)
31/03/2026 13:44
March 31 (Reuters) - Tarsus Pharmaceuticals Inc TARS.O: TARSUS DOSES FIRST PARTICIPANT IN CALLIOPE, A PHASE 2 CLINICAL TRIAL OF TP-05 (LOTILANER), A NOVEL INVESTIGATIONAL ORAL TABLET FOR THE POTENTIAL PREVENTION OF LYME DISEASE TARSUS PHARMACEUTICALS INC - ENROLLMENT TO COMPLETE IN 2026 TICK SEASON, TOPLINE RESULTS EXPECTED FIRST HALF 2027 Source text: ID:nGNX9F7smd Further company coverage: TARS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)